Proteome Sciences Sees Recovery in Reagent Sales and Strong Proteomics Outlook

Proteome Sciences ( (GB:PRM) ) just unveiled an announcement.

Proteome Sciences reported progress in its services business, noting improved order levels and a continuing recovery in sales of its TMT and other reagents in the first half of the year. The company said recent investments over the past two years have strengthened its position to capitalise on growth in the proteomics market and to generate substantial returns for stakeholders.

Management emphasised that the rebound in demand follows prior funding cuts to U.S. NIH budgets and academic research grants in 2025. This recovery, combined with capacity built through earlier investment, is expected to enhance operational performance and support the company’s competitive standing in a fast-growing segment of the life sciences industry.

Spark’s Take on PRM Stock

According to Spark, TipRanks’ AI Analyst, PRM is a Neutral.

The score is primarily constrained by weak financial performance, driven by declining revenue, negative gross profit, sustained losses, and a stressed balance sheet with rising debt and deeply negative equity. Technicals are only mildly supportive (short-term rebound but still below the 200-day average with negative MACD), while valuation is hindered by ongoing losses (negative P/E) and no dividend data.

To see Spark’s full report on PRM stock, click here.

More about Proteome Sciences

Proteome Sciences plc is a life sciences company focused on proteomics, providing specialist protein analysis services and related reagents. Its business targets research and development markets, including academic and government-funded laboratories, particularly those supported by U.S. National Institutes of Health grants.

Average Trading Volume: 261,362

Technical Sentiment Signal: Sell

Current Market Cap: £6.14M

For an in-depth examination of PRM stock, go to TipRanks’ Overview page.